RE:RE:RE:RE:RE:RE:RE:RE:Kol event The thing that's odd is they kept blaming EMA for the delays from time of the FDA study may proceed letter to the July Earnings Call. But in the call with Canacord, they said conversations with the EMA went very smoothly... and Paul seemed to imply it went off without a hitch. So there's a lag in the timeline that could be explained by partnership talks, but isn't explained on Theras own terms. But a delay in developing partnership discussions could explain the turnabout from dosing in September to open to a partner in the earnings call. Im obviously speculating, but the NASH timelines don't make sense from what Thera has said publicly and when the study may proceed letter came out. Any other thoughts on that?